Safiri, S. et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. Bmj 378, e069679 (2022).

Google Scholar 

Wang, Z. et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir. Res. 24, 169 (2023).

Google Scholar 

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, www.ginasthma.org (2023).

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD, www.goldcopd.org (2023).

MCTOC: Medical and Chemical Technical Options Committee. 2018 Assessment Report, https://ozone.unep.org/sites/default/files/2019-04/MCTOC-Assessment-Report-2018.pdf (2018).

Wilkinson, A. J. K., Braggins, R., Steinbach, I. & Smith, J. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ open. 9, e028763 (2019).

Google Scholar 

Lenzen, M. et al. The environmental footprint of health care: a global assessment. Lancet Planet. Health 4, e271–e279 (2020).

Google Scholar 

Pichler, P.-P., Jaccard, I. S., Weisz, U. & Weisz, H. International comparison of health care carbon footprints. Environ. Res. Lett. 14, 064004 (2019).

Google Scholar 

NHS England. Delivering a Net Zero National Health Service, https://www.england.nhs.uk/greenernhs/a-net-zero-nhs/ (2021).

Lavorini, F. et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir. Med. 105, 1099–1103 (2011).

Google Scholar 

Wilkinson, A. & Woodcock, A. The environmental impact of inhalers for asthma: A green challenge and a golden opportunity. Br. J. Clin. Pharmacol. 88, 3016–3022 (2022).

Google Scholar 

British Thoracic Society and Scottish Intercollegiate Guideline Network. BTS/SIGN British guideline on the management of asthma: A national clinical guideline, https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/ (2019).

Brocklebank, D., Wright, J. & Cates, C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Bmj 323, 896–900 (2001).

Google Scholar 

Dolovich, M. B. et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127, 335–371 (2005).

Google Scholar 

Ram, F. S., Brocklebank, D. M., Muers, M., Wright, J. & Jones, P. W. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2002, Cd002170 (2002).

Google Scholar 

Ram, F. S., Wright, J., Brocklebank, D. & White, J. E. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2)agonists bronchodilators in asthma. Bmj 323, 901–905 (2001).

Google Scholar 

Department of Health and Aged Care. National Health and Climate Strategy, https://www.health.gov.au/our-work/national-health-and-climate-strategy (2023).

Loftus M. J. et al. Systematic Review Protocol - Metered Dose inhalers versus Dry Powder Inhalers and Soft Mist Inhalers for Asthma and COPD, https://doi.org/10.26180/26065789.v2 (2024).

Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj 372, n71 (2021).

Google Scholar 

National Institute for Health and Care Excellence (NICE). Inhaled corticosteroid doses for NICE’s asthma guideline, https://www.nice.org.uk/guidance/ng80/resources/inhaled-corticosteroid-doses-pdf-4731528781 (2023).

Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia, 2024).

Rohatgi A. WebPlotDigitizer version 5.1, https://automeris.io (2024).

Higgins J. P. T. & Altman D. G. in Cochrane Handbook for Systematic Reviews of Interventions (eds Higgins J. P. T. & Green S.) (John Wiley & Sons, 2008).

The Cochrane Collaboration. Review Manager (RevMan). Version 8.5.2, www.revman.cochrane.org (2024).

Schünemann HJ, H. J. et al. in Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (ed Thomas J. Higgins J. P. T., Chandler J., Cumpston M., Li T., Page M. J., Welch V. A.) (Cochrane, 2023).

Santesso, N. et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J. Clin. Epidemiol. 119, 126–135 (2020).

Google Scholar 

Pellegrino, R. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 26, 948–968 (2005).

Google Scholar 

Donohue, J. F. Minimal clinically important differences in COPD lung function. Copd 2, 111–124 (2005).

Google Scholar 

Santanello, N. C., Zhang, J., Seidenberg, B., Reiss, T. F. & Barber, B. L. What are minimal important changes for asthma measures in a clinical trial?. Eur. Respir. J. 14, 23–27 (1999).

Google Scholar 

Karras, D. J. et al. Clinically meaningful changes in quantitative measures of asthma severity. Acad. Emerg. Med. 7, 327–334 (2000).

Google Scholar 

Dissanayake, S., Jain, M., Grothe, B., McIver, T. & Papi, A. An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. Pulmonary Pharmacology Therapeutics 35, 19–27 (2015).

Google Scholar 

Costello, A. et al. Managing the health effects of climate change: lancet and university college london institute for global health commission. Lancet 373, 1693–1733 (2009).

Google Scholar 

Vicedo-Cabrera, A. M. et al. Climate change and respiratory health: a european respiratory society position statement. Eur. Respir. J. 62, 2201960 (2023).

Google Scholar 

Pernigotti, D. et al. Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries. BMJ Open. Respir. Res. 8, e001071 (2021).

Google Scholar 

Murphy, A., Howlett, D., Gowson, A. & Lewis, H. Understanding the feasibility and environmental effectiveness of a pilot postal inhaler recovery and recycling scheme. NPJ Prim. Care Respir. Med. 33, 5 (2023).

Google Scholar 

Wilkinson, A. J. K. et al. Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment (CARBON) study. Thorax 79, 412–421 (2024).

Google Scholar 

Lavorini, F., Janson, C., Braido, F., Stratelis, G. & Løkke, A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther. Adv. Respir. Dis. 13, 1753466619884532 (2019).

Google Scholar 

British Thoracic Society. Position Statement Sustainability and the Environment: Climate Change & Lung Health, https://www.brit-thoracic.org.uk/about-us/position-statements/ (2024).

National Institute for Health and Care Excellence (NICE). Patient Decision Aid: Inhalers for Asthma, https://www.nice.org.uk/guidance/ng80/resources/inhalers-for-asthma-patient-decision-aid-pdf-6727144573/ (2020).

Parker, J. Barriers to green inhaler prescribing: ethical issues in environmentally sustainable clinical practice. J. Med. Ethics 49, 92–98 (2023).

Google Scholar 

Keeley, D., Scullion, J. E. & Usmani, O. S. Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. Eur. Respir. J. 55, 2001122 (2020).

Google Scholar 

D’Ancona, G., Cumella, A., Renwick, C. & Walker, S. The sustainability agenda and inhaled therapy: what do patients want?. European Respiratory Journal 58, PA3399 (2021).

Google Scholar 

Liew, K. & Wilkinson, A. P280 How do we choose inhalers? patient and physician perspectives on environmental, financial and ease-of-use factors. Thorax 72, A235–A237 (2017).

Google Scholar 

Metting, E. I., Dijk, L. V., Messlaki, H. E., Luers, J. & Kock, J. Development of a shared decision-making tool to support patients and their healthcare provider in choosing the best inhaler device. Eur. Respiratory J. 52, OA1643 (2018).

Google Scholar 

Woodcock, A. et al. The environmental impact of inhaled therapy: making informed treatment choices. Eur. Respir. J. 60, 2102106 (2022).

Google Scholar 

Clark, A. R., Weers, J. G. & Dhand, R. The confusing world of dry powder inhalers: it is all about inspiratory pressures, not inspiratory flow rates. J. Aerosol Med. Pulm. Drug. Deliv. 33, 1–11 (2020).

Google Scholar 

Mahler, D. A., Waterman, L. A., Ward, J. & Gifford, A. H. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J. Aerosol Med. Pulm. Drug. Deliv. 27, 103–109 (2014).

Google Scholar 

Sharma, G. et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr. Pulm. Dis. 4, 217–224 (2017).

Google Scholar 

Kuek, S. L. et al. Dry powder inhaler use in primary school aged children with asthma: a systematic review. ERJ Open. Res. 10, 00455–02024 (2024).

Google Scholar 

Price, D. B. et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J. Allergy Clin. Immunol. Pract. 5, 1071–1081.e1079 (2017).

Google Scholar 

Usmani, O. S. et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir. Res. 19, 10 (2018).

Google Scholar 

Vestbo, J. et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N. Engl. J. Med. 375, 1253–1260 (2016).

Google Scholar 

Woodcock, A. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet 390, 2247–2255 (2017).

Google Scholar 

Jones, R. et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int. J. Chron. Obstruct Pulmon Dis. 12, 2445–2454 (2017).

Google Scholar 

Price, D. et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir. Med. 105, 1457–1466 (2011).

Google Scholar 

Usmani, O. S. et al. Real-world impact of nonclinical inhaler regimen switches on asthma or COPD: a systematic review. J. Allergy Clin. Immunol. Pract. 10, 2624–2637 (2022).

Google Scholar 

Thomas, M. et al. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm. Med. 9, 1 (2009).

Google Scholar 

Price, D. et al. Switching patients from other inhaled corticosteroid devices to the Easyhaler(®): historical, matched-cohort study of real-life asthma patients. J. Asthma Allergy 7, 31–51 (2014).

Google Scholar 

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials E10. ICH: Geneva, 2000.

Google Scholar 

Amar, N. J., Shekar, T., Varnell, T. A., Mehta, A. & Philip, G. Mometasone furoate (MF) improves lung function in pediatric asthma: A double-blind, randomized controlled dose-ranging trial of MF metered-dose inhaler. Pediatr. Pulmonol. 52, 310–318 (2017).

Google Scholar 

Corrigendum. Pediatr Pulmonol. 54: 655–656. https://doi.org/10.1002/ppul.24291.

Barnes, N. et al. Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination. Pulm. Pharmacol. Ther. 26, 555–561 (2013).

Google Scholar 

Bateman, E. D., Silins, V. & Bogolubov, M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir. Med. 95, 136–146 (2001).

Google Scholar 

Bernstein, D. I. et al. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma. Allergy Asthma Clin. Immunol. 7, 21 (2011).

Google Scholar 

Bodzenta-Lukaszyk, A. et al. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J. Asthma 49, 1060–1070 (2012).

Google Scholar 

Bracamonte, T., Schauer, U., Emeryk, A., Godwood, A. & Balsara, S. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the diskustrade mark or pressurised metered-dose inhaler in children with asthma. Clin. Drug. Investig. 25, 1–11 (2005).

Google Scholar 

Bronsky, E. et al. Comparison of inhaled albuterol powder and aerosol in asthma. J. Allergy Clin. Immunol. 79, 741–747 (1987).

Google Scholar 

Busse, W. W. et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J. Allergy Clin. Immunol. 121, 1407–1414 (2008). 1414.e1401-1406.

Google Scholar 

O’Connor, R. D., Patrick, D. L., Parasuraman, B., Martin, P. & Go